1. |
Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: Key points for the radiologist. Radiology, 2020, 295(1): 16-17.
|
2. |
Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol, 2017, 35(7): 709-717.
|
3. |
Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol, 2016, 27(7): 1362.
|
4. |
Suresh K, Voong KR, Shankar B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors. J Thorac Oncol, 2018, 13(12): 1930-1939.
|
5. |
Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. Chest, 2017, 152(2): 271-281.
|
6. |
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus ocetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med, 2015, 373(2): 123-135.
|
7. |
Hida T, Nishio M, Nogami N, et al. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci, 2017, 108(5): 1000-1006.
|
8. |
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med, 2015, 373(17): 1627-1639.
|
9. |
Lisberg A, Cummings A, Goldman JW, et al. A phase Ⅱ study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol, 2018, 13(8): 1138-1145.
|
10. |
Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol, 2018, 4(8): 1112-1115.
|
11. |
Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J, 2017, 50(2): 1700050.
|
12. |
Wu C, Zheng S, ChenY, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. MedRxiv, 2020. [Epub ahead of print].
|
13. |
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020. [Epub ahead of print].
|
14. |
Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review. JAMA, 2019, 322(8): 764-774.
|
15. |
Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small cell lung cancer treated with pembrolizumab: Results from the phase Ⅰ KEYNOTE-001 study. J Clin Oncol, 2019, 37(28): 2518-2527.
|
16. |
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med, 2019, 381(21): 2020-2031.
|
17. |
Im SJ, Hashimoto M, Gerner MY, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature, 2016, 537(7620): 417-421.
|
18. |
Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol, 2018, 36(28): 2872-2878.
|
19. |
Ricciuti B, Dahlberg SE, Adeni A, et al. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol, 2019, 37(22): 1927-1934.
|
20. |
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med, 2020. [Epub ahead of print].
|
21. |
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, 395(10222): 391-393.
|
22. |
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020. [Epub ahead of print].
|